The Drugs Controller General of India (DCGI) has given permission for conducting Phase-1 human scientific trial for an “antisera” that was developed by injecting inactivated SARS-CoV-2 in horses and generally is a potential therapy for COVID-19. The ‘antisera’ has been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical agency.
“With Biological E Limited we have developed an horse ‘antisera’ and we have just got clearance for conducting clinical trials for that,” ICMR Director General Dr Balram Bhargava mentioned at press briefing on Tuesday.
As a part of the research, 10 wholesome horses had been immunised with inactivated SARS-CoV-2 and after 21 days of immunisation, plasma samples had been examined.
The outcomes of the plasma samples indicated presence of SARS-CoV-2 particular IgG antibodies as detected in ELISA with neutralising capability.
The ‘antisera’ is but to endure human scientific trials to ascertain security and efficacy. Antisera are blood serum excessive in antibodies in opposition to particular antigens and are injected in people to assist kickstart the immune system to struggle particular infections.
The pre-print model of the research relating to the event of the equine antisera has been posted on the Research Square platform.
“The study provides evidence of the potential of generating highly purified F(ab’)2 from equines against SARS-CoV-2 that can demonstrate consistent and high neutralisation activity,” the research paper mentioned.
“Further, in-vivo testing for efficacy of this indigenously developed, cost effective product will pave the way to clinical evaluation.
Additionally, being a donor independent method, this may prove as an efficient alternative to convalescent plasma for treatment of COVID-19 patients,” it mentioned.
Earlier such measures had been used for controlling a number of viral and bacterial infections.
“Although, plasma recovered from patients experiencing COVID-19 could serve similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore, make it an unreliable clinical tool for patient management,” the ICMR had mentioned in a tweet.
“Standardisation achievable through equine sera based treatment modality thus stands out as yet another remarkable public health initiative supported by ICMR in the time of COVID-19,” it mentioned.
(With PTI inputs)